AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20090438 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of intraperitoneal lidocaine
Number of subjects: 370
Study 20090438 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (0.9%)
Number of subjects: 370
Study 18171451 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dose + placebo
Number of subjects: 26
Study 18171451 — intervention group
Group type: COMPARATOR
Intervention: 50% dose
Number of subjects: 26
Study 18171451 — intervention group
Group type: COMPARATOR
Intervention: Baseline (100%) dose
Number of subjects: 26
Study 16606810 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (OG group)
Number of subjects: 4081
Study 16606810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OP group)
Number of subjects: 4081
Study 14613506 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-rich protein formula
Number of subjects: 0
Study 14613506 — intervention group
Group type: COMPARATOR
Intervention: Standard solution
Number of subjects: 0
Study 14613506 — intervention group
Group type: COMPARATOR
Intervention: Free glutamine formula
Number of subjects: 0
Study 10908209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus coumarins
Number of subjects: 1058
Study 10908209 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1058
Study 8757358 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin or tobramycin (4 mg/kg IV)
Number of subjects: 96
Study 8757358 — intervention group
Group type: COMPARATOR
Intervention: Pharmacokinetic dosing (initial dose of 2 mg/kg IV every 12 hours)
Number of subjects: 96
Study 8757358 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing and pharmacokinetic dosing of aminoglycosides
Number of subjects: 96
Study 1434581 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance program
Number of subjects: 60
Study 1434581 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk-jog program
Number of subjects: 60
Study 1434581 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 60
Study 3931448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 133
Study 3931448 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 133
Study 31228505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable Maths Masters app
Number of subjects: 74
Study 31228505 — intervention group
Group type: COMPARATOR
Intervention: Control app (similar but did not include any foods)
Number of subjects: 74
Study 29913254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 fractions (7.25 Gy in 2 weeks)
Number of subjects: 255
Study 29913254 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 fractions (4.3 Gy in 2.5 weeks)
Number of subjects: 255
Study 27106890 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 clinical trials
Number of subjects: 29
Study 25195982 — intervention group
Group type: EXPERIMENTAL
Intervention: DART (Dispatcher-Assisted Randomized Trial)
Number of subjects: 8626
Study 22301472 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 100
Study 22301472 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 100
Study 20228513 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (either orally or intravenously) with hydration using sodium bicarbonate
Number of subjects: 280
Study 20228513 — intervention group
Group type: COMPARATOR
Intervention: Hydration with sodium bicarbonate only
Number of subjects: 280
Study 17429316 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine (0.1 mg/kg)
Number of subjects: 22
Study 17429316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15117142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 250
Study 15117142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin, Ofloxacin, Gentamycin
Number of subjects: 250
Study 15117142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin, Ofloxacin, Erythromycin, Ciprofloxacin, Gentamicin, Tetracycline
Number of subjects: 250
Study 15117142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 250
Study 11561215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 50% sunflower oil (1.5 g/kg) followed by FSIVGTT 4 h later (test 2)
Number of subjects: 17
Study 11561215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 50% sunflower oil (1.5 g/kg) with i.v. addition of 100 U/kg heparin prior to FSIVGTT (test 3)
Number of subjects: 17
Study 11561215 — intervention group
Group type: COMPARATOR
Intervention: Control (test 1: FSIVGTT, 0.3 g/kg glucose)
Number of subjects: 17
Study 11561215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of sunflower oil triglyceride emulsion
Number of subjects: 17
Study 11561215 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-induced high levels of FFA (test 3)
Number of subjects: 17
Study 9743819 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 800 mg per day
Number of subjects: 42
Study 9743819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 42
Study 9743819 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 42
Study 7945623 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe antepartum preeclampsia and eclamptic seizures after cesarean section and subtotal hysterectomy
Number of subjects: 1
Study 3174030 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine‐125 plaque irradiation
Number of subjects: 0
Study 3174030 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0
Study 28691363 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma Australia educational intervention (telephone-based counselling and mail-out information)
Number of subjects: 101
Study 28691363 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care and information from treating ophthalmologist)
Number of subjects: 101
Study 28691363 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma Australia educational intervention
Number of subjects: 101
Study 28691363 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 28691363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 26520169 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 124
Study 26520169 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab
Number of subjects: 124
Study 26520169 — intervention group
Group type: EXPERIMENTAL
Intervention: VMA+ group
Number of subjects: 124
Study 25601227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Olixia pure(®) ; Croma Pharma, Korneuburg, Austria) eye drops
Number of subjects: 16
Study 25601227 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution (placebo control)
Number of subjects: 16
Study 23664526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 181
Study 23664526 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 181
Study 21040582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrotose AO® (4 capsules per day = 2 grams per day)
Number of subjects: 25
Study 21040582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrotose AO®
Number of subjects: 25
Study 21040582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18706769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine medications
Number of subjects: 8
Study 18706769 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 16357350 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-based clinical decision support system (CDSS) for NSAID prescribing
Number of subjects: 0
Study 16357350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDSS)
Number of subjects: 0
Study 14618061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate Smoothing (RS) On
Number of subjects: 219
Study 14618061 — intervention group
Group type: COMPARATOR
Intervention: Rate Smoothing (RS) Off
Number of subjects: 219
Study 15055252 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 117
Study 15055252 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 117
Study 10029122 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning and home follow‐up protocol by advanced practice nurses
Number of subjects: 363
Study 10029122 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 363
Study 8616475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 estimation by immunoenzymatic assay (Enzymun Cyfra 21-1) in lung cancer patients
Number of subjects: 153
Study 8616475 — intervention group
Group type: COMPARATOR
Intervention: Control group (benign lung diseases)
Number of subjects: 153
Study 8616475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 estimation in advanced lung cancer stages
Number of subjects: 153
Study 8616475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 estimation in small cell lung cancer
Number of subjects: 153
Study 2183804 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (0.15-0.20 mg/kg/day)
Number of subjects: 231
Study 2183804 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 231
Study 2183804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 2183804 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin and Placebo
Number of subjects: 231
Study 7307563 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple gel (sequential application of Keralyt, Estar, and Topsyn gels)
Number of subjects: 30
Study 7307563 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent salicylic acid in Sofsyn oil
Number of subjects: 30
Study 7307563 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent salicylic acid in mineral oil
Number of subjects: 30
Study 31741068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral serratus plane block with 0.25% bupivacaine 30 ml each side
Number of subjects: 40
Study 31741068 — intervention group
Group type: COMPARATOR
Intervention: Control group received bilateral ultrasound-guided 2 ml 0.9% saline subcutaneously each block side
Number of subjects: 40
Study 28143456 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg in combination with metformin 1000 mg BID
Number of subjects: 30
Study 28143456 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 3 mg QD alone
Number of subjects: 30
Study 25590472 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal intradermal suturing
Number of subjects: 0
Study 25590472 — intervention group
Group type: COMPARATOR
Intervention: External intradermal suturing
Number of subjects: 0
Study 24215592 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day fasting (ADF)
Number of subjects: 32
Study 24215592 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 21455122 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (multicomponent lifestyle intervention)
Number of subjects: 507
Study 21455122 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss/maintenance group (n = 154)
Number of subjects: 507
Study 19723864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 113
Study 19723864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 113
Study 17766602 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ uterine repair
Number of subjects: 80
Study 17766602 — intervention group
Group type: COMPARATOR
Intervention: Exteriorized uterine repair
Number of subjects: 80
Study 15066065 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0677
Number of subjects: 161
Study 15066065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 11495047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg d(-1)
Number of subjects: 16
Study 11495047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg d(-1)
Number of subjects: 16
Study 9763323 — intervention group
Group type: EXPERIMENTAL
Intervention: BOMP (probing marginal gingiva)
Number of subjects: 25
Study 9763323 — intervention group
Group type: EXPERIMENTAL
Intervention: BOPP (probing to the bottom of the pocket)
Number of subjects: 25
Study 9763323 — intervention group
Group type: EXPERIMENTAL
Intervention: BOMP
Number of subjects: 25
Study 9763323 — intervention group
Group type: EXPERIMENTAL
Intervention: BOPP
Number of subjects: 25
Study 9763323 — intervention group
Group type: COMPARATOR
Intervention: BOMP and BOPP
Number of subjects: 25
Study 7824425 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream 0.025% applied twice daily
Number of subjects: 1
Study 2901565 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (30 micrograms/kg intravenous bolus followed by 30 micrograms/kg/h infusion)
Number of subjects: 14
Study 2901565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent volume bolus and infusion)
Number of subjects: 14
Study 31694759 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 53
Study 31694759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31856908 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-frequency stimulation (VFS)
Number of subjects: 0
Study 31856908 — intervention group
Group type: COMPARATOR
Intervention: Constant-frequency stimulation
Number of subjects: 0
Study 28008691 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP therapist training (FAPTT) course, eight weekly sessions
Number of subjects: 25
Study 28008691 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 25
Study 26228365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (Esomeprazole 20 mg bid for 10 days, amoxicillin 1000 mg for 5 days, then clarithromycin 500 mg and tinidazole 500 mg; both bid for 5 days)
Number of subjects: 232
Study 26228365 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (Esomeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1000 mg each bid for 14 days)
Number of subjects: 232
Study 23754238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX), n = 99
Number of subjects: 197
Study 23754238 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide followed by Azathioprine (CYC/AZA), n = 98
Number of subjects: 197
Study 20966901 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid protein meal (steamed chicken breast + 750 ml water)
Number of subjects: 10
Study 20966901 — intervention group
Group type: COMPARATOR
Intervention: Liquefied protein meal (steamed chicken breast blended in 500 ml water + 250 ml water)
Number of subjects: 10
Study 22009776 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaBone grafting at fracture site
Number of subjects: 78
Study 22009776 — intervention group
Group type: COMPARATOR
Intervention: Control group (without NovaBone grafting)
Number of subjects: 78
Study 17721754 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 46
Study 17721754 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 46
Study 17721754 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 46
Study 15216404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% brinzolamide ophthalmic solution
Number of subjects: 50
Study 15216404 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 50
Study 12470761 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-Gy proton irradiation delivered in two fractions 24 hours apart
Number of subjects: 37
Study 12470761 — intervention group
Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 37
Study 10680493 — intervention group
Group type: EXPERIMENTAL
Intervention: rHGH (0.3u.Kg‐1 subcutaneously at 8 am each morning for 10 days)
Number of subjects: 16
Study 10680493 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 16
Study 7609294 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms.kg‐1 orally
Number of subjects: 20
Study 7609294 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam 0.1 mg.kg‐1 90 min prior to arrival in the operating room (Control)
Number of subjects: 20
Study 2229458 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 45 mg
Number of subjects: 30
Study 2229458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 636912 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK) and lactate dehydrogenase isoenzymes analyzed with a column chromatographic method.
Number of subjects: 201
Study 636912 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase isoenzyme specificity for myocardial damage.
Number of subjects: 201
Study 30358572 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-side position (RRP)
Number of subjects: 90
Study 30358572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal position (DRP)
Number of subjects: 90
Study 30358572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined position
Number of subjects: 90
Study 30358572 — intervention group
Group type: COMPARATOR
Intervention: All groups (RRP, DRP, Combined)
Number of subjects: 90
Study 29251975 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment plus Contingency Management (STCM)
Number of subjects: 65
Study 29251975 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment Alone (STA)
Number of subjects: 65
Study 26064990 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 51
Study 26064990 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 51
Study 26064990 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 51
Study 23479911 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 100
Study 22224344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 100
Study 22224344 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectables
Number of subjects: 100
Study 22224344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-uterine device
Number of subjects: 100
Study 22224344 — intervention group
Group type: COMPARATOR
Intervention: Control (non-contraceptive users)
Number of subjects: 100
Study 19328267 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice containing 50 mg DHA daily for 6 weeks
Number of subjects: 0
Study 19328267 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice containing 100 mg DHA daily for 6 weeks
Number of subjects: 0
Study 16939483 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (10 ml of 4% lidocaine)
Number of subjects: 44
Study 16939483 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 44
Study 15312157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 8 mg of 14C‐labelled TCC
Number of subjects: 0
Study 15312157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of TCC and M1
Number of subjects: 0
Study 15312157 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of TCC vs. intramuscular administration
Number of subjects: 0
Study 15312157 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of muscle relaxant activity of M1 and M2
Number of subjects: 0
Study 15312157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioanalytical method for TCC and M1
Number of subjects: 0
Study 11745909 — intervention group
Group type: EXPERIMENTAL
Intervention: Andolast 2 mg
Number of subjects: 12
Study 11745909 — intervention group
Group type: EXPERIMENTAL
Intervention: Andolast 4 mg
Number of subjects: 12
Study 11745909 — intervention group
Group type: EXPERIMENTAL
Intervention: Andolast 8 mg
Number of subjects: 12
Study 11745909 — intervention group
Group type: EXPERIMENTAL
Intervention: Andolast (all doses)
Number of subjects: 12
Study 9290300 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term passive heat exposure during military training
Number of subjects: 30
Study 8329700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 441
Study 8329700 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 441
Study 8329700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (primary therapy)
Number of subjects: 441
Study 8329700 — intervention group
Group type: COMPARATOR
Intervention: Busulfan (primary therapy)
Number of subjects: 441
Study 3546618 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance BCG therapy (six-weekly doses of BCG plus monthly BCG for 2 years)
Number of subjects: 93
Study 3546618 — intervention group
Group type: COMPARATOR
Intervention: Nonmaintenance BCG therapy (BCG weekly for 6 weeks)
Number of subjects: 93
Study 3546618 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance BCG therapy
Number of subjects: 93
Study 3546618 — intervention group
Group type: COMPARATOR
Intervention: Nonmaintenance BCG therapy
Number of subjects: 93
Study 3546618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Maintenance and Nonmaintenance BCG therapy)
Number of subjects: 93
Study 3546618 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of tumor after induction BCG
Number of subjects: 93
Study 3546618 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive tuberculin skin test before and after induction BCG
Number of subjects: 93
Study 31455090 — intervention group
Group type: EXPERIMENTAL
Intervention: MCH‐ART integrated service
Number of subjects: 21
Study 31455090 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (immediate postpartum referral to separate services)
Number of subjects: 21
Study 30630796 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery, antibiotics, and wuwei xiaodu drink
Number of subjects: 80
Study 30630796 — intervention group
Group type: COMPARATOR
Intervention: Surgery and antibiotics
Number of subjects: 80
Study 26907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PPI (30 mg lansoprazole twice a day)
Number of subjects: 166